Novocure rises after FDA accepts premarket application for cancer treatment

NovoCure

18/01/2024 16:13

(Updates)
    ** Shares of Novocure  NVCR.O  rise 18.2% to $14.68 in
morning trade
        ** Stock set for its biggest one day pct. rise in over a
year if gains hold
  
    ** Company says the U.S. FDA has accepted its application
for premarket approval for its device Tumor Treating Fields, for
a type lung cancer, in combination with either chemotherapy or a
cancer immunotherapy
    ** NVCR expects to receive a regulatory decision from the
FDA in H2 2024
    ** Stock down 84.1% in the last 12 months

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))